Disclosures. Objectives 11/2/2015. Type 2 Diabetes Mellitus: Medication Update. Diabetes Recommendations. Main Pathophysiological Defects in T2DM
|
|
- Reginald Stevenson
- 6 years ago
- Views:
Transcription
1 Type 2 Diabetes Mellitus: Medication Update Which One Should the NP Use? Iowa Nurse Practitioner Society Dr. Dixie Harms, DNP, ARNP, FNP-C, BC-ADM, FAANP November 2015 Disclosures Speaker s Bureau Novo Ndisk Objectives Diabetes Recommendations After completion of this class, the NP should be able to: Review the pathophysiology of diabetes. Describe pharmacotherapeutics f patients with diabetes. Apply knowledge of pharmacotherapeutics to selected case studies ADA Recommendations Published annually in January supplement of Diabetes Care Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient- Centered Approach Update to a Position Statement of the American Diabetes Association and the European Association f the Study of Diabetes Published: Diabetes Care 2015;38: American Association Of Clinical Endocrinologists And American College Of Endocrinology Clinical Practice Guidelines F Developing A Diabetes Mellitus Comprehensive Care Plan 2015 Obesity (BMI 30 kg/m 2 ) 1994 Diabetes Age-adjusted Prevalence of Obesity and Diagnosed Diabetes Among US Adults No Data <14.0% 14.0% 17.9% 18.0% 21.9% 22.0% 25.9% > 26.0% Main Pathophysiological Defects in T2DM incretin effect gut carbohydrate delivery & absption - pancreatic insulin secretion pancreatic glucagon secretion HYPERGLYCEMIA? No Data <4.5% 4.5% 5.9% 6.0% 7.4% 7.5% 8.9% >9.0% CDC s Division of Diabetes Translation. National Diabetes Surveillance System available at hepatic glucose production - peripheral glucose uptake Adapted from: Inzucchi SE, Sherwin RS in: Cecil Medicine
2 Glycemic Management of Type 2 Diabetes Therapeutic Lifestyle Change Incretin secretion, action in the natural histy of type 2 diabetes ENDOCRINE TODAY March Components of Therapeutic Lifestyle Change AACE Recommendations: Therapeutic Lifestyle Changes Healthful eating Sufficient physical activity Sufficient sleep Avoidance of tobacco products Limited alcohol consumption Stress reduction Parameter Weight loss (f overweight and obese patients) Physical activity Diet Treatment Goal Reduce by 5% to 10% 150 min/week of moderate-intensity exercise (eg, brisk walking) plus flexibility and strength training Eat regular meals and snacks; avoid fasting to lose weight Consume plant-based diet ( in fiber, low calies/glycemic index, and in phytochemicals/antioxidants) Understand Nutrition Facts Label infmation Incpate beliefs and culture into discussions Use mild cooking techniques instead of -heat cooking Keep physician-patient discussions infmal 9 10 AACE Recommendations: Healthful Eating AACE Recommendations: Medical Nutritional Therapy Carbohydrate Fat Protein Micronutrients Specify healthful carbohydrates (fresh fruits and vegetables, legumes, whole grains); target 7-10 servings per day Preferentially consume lower-glycemic index foods (glycemic index sce <55 out of 100: multigrain bread, pumpernickel bread, whole oats, legumes, apple, lentils, chickpeas, mango, yams, brown rice) Specify healthful fats (low mercury/contaminant-containing nuts, avocado, certain plant oils, fish) Limit saturated fats (butter, fatty red meats, tropical plant oils, fast foods) and trans fat; choose fat-free low-fat dairy products Consume protein in foods with low saturated fats (fish, egg whites, beans); there is no need to avoid animal protein Avoid limit processed meats Routine supplementation is not necessary; a healthful eating meal plan can generally provide sufficient micronutrients Chromium; vanadium; magnesium; vitamins A, C, and E; and CoQ10 are not recommended f glycemic control Vitamin supplements should be recommended to patients at risk of insufficiency deficiency Consistency in day-to-day carbohydrate intake Carb counting Limitation of sucrose-containing -glycemic index foods Adequate protein intake Heart-healthy diets Weight management Exercise Self-moniting blood glucose
3 Glycemic Management of Type 2 Diabetes Antihyperglycemic Therapy Principles of the AACE/ACE Type 2 Diabetes Algithm Glucose Targets Ongoing lifestyle optimization essential Requires suppt from full diabetes team Set A1C target based on individual patient characteristics and risk 6.5% optimal if it can be achieved safely Targets may change over time Glucose moniting essential to evaluating therapy effectiveness FPG and PPG regularly monited by patient with SMBG A1C and SMBG recds monited by clinician 13 FPG, fasting plasma glucose; PPG, postprandial glucose; SMBG, self-moniting of blood glucose. 14 Principles of the AACE/ACE Type 2 Diabetes Algithm Choose medications based on individual patient attributes Minimize risk of hypoglycemia Minimize risk of weight gain Combine agents with complimentary mechanisms of action f optimal glycemic control Priitize safety and efficacy over medication cost Medication cost small ption of total cost of diabetes Risk of adverse effects considered part of cost of medication Antihyperglycemic Medications Evaluate treatment efficacy every 3 months A1C, FPG, and PPG data Hypoglycemia Other adverse events (weight gain; fluid retention; hepatic, renal, cardiac disease) Combidities and complications Concomitant drugs Psychosocial facts affecting patient care ADA/EASD DM2 Treatment Algithm Monotherapy Dual therapy Triple therapy Efficacy * Hypo risk Weight Side effects Costs Efficacy * Hypo risk Weight Side effects Costs Healthy eating, weight control, increased physical activity & diabetes education Metfmin low risk neutral/loss GI / lactic acidosis low If HbA1c target not achieved after ~3 months of monotherapy, proceed to 2-drug combination (der not meant to denote any specific preference - choice dependent on a variety of patient- & disease-specific facts): Metfmin Sulfonylurea moderate risk gain hypoglycemia low Metfmin Sulfonylurea TZD DPP-4-i SGLT2-i Metfmin Thiazolidinedione low risk gain edema, HF, fxs low Metfmin Thiazolidinedione SU DPP-4-i SGLT2-i Metfmin DPP-4 inhibit intermediate low risk neutral rare Metfmin DPP-4 Inhibit SU TZD SGLT2-i Metfmin SGLT2 inhibit intermediate low risk loss GU, dehydration SGLT-2 Inhibit Metfmin SU TZD DPP-4-i Metfmin GLP-1 recept agonist low risk loss GI If HbA1c target not achieved after ~3 months of dual therapy, proceed to 3-drug combination (der not meant to denote any specific preference - choice dependent on a variety of patient- & disease-specific facts): Metfmin GLP-1 recept agonist SU TZD Insulin Metfmin Insulin (basal) est risk gain hypoglycemia variable Metfmin Insulin (basal) TZD DPP-4-i SGLT2-i Oral Agents f DM2 Class Primary Mechanism of Action Agent(s) Available as Delay carbohydrate absption from Acarbose Precose generic -Glucosidase inhibits intestine Miglitol Glyset Decrease glucagon secretion Amylin analogue Slow gastric emptying Pramlintide Symlin Increase satiety Decrease hepatic glucose production Biguanide Metfmin Glucophage generic Increase glucose uptake in muscle Decrease hepatic glucose production? Bile acid sequestrant Colesevelam WelChol Increase incretin levels? Alogliptin Nesina Increase glucose-dependent insulin Linagliptin Tradjenta DPP-4 inhibits secretion Saxagliptin Onglyza Decrease glucagon secretion Sitagliptin Januvia Combination injectable therapy GLP-1-RA Insulin GLP-1-RA Insulin Basal Insulin Insulin Insulin GLP-1-RA If HbA1c target not achieved after ~3 months of triple therapy and patient (1) on al combination, move to injectables, (2) on GLP-1 RA, add basal insulin, (3) on optimally titrated basal insulin, add GLP-1-RA mealtime insulin. In refracty patients consider adding TZD SGL T2-i: Metfmin Mealtime Insulin GLP-1-RA Inzucchi SE, et al. Diabetes Care. 2012;35: Dopamine-2 agonist Activates dopaminergic recepts Bromocriptine Cycloset Nateglinide Starlix generic Glinides Increase insulin secretion Repaglinide Prandin DPP-4, dipeptidyl peptidase; HGP, hepatic glucose production. 3
4 Oral Agents f DM2 Effects of Agents Available f DM2 Class Primary Mechanism of Action Agent(s) Available as SGLT2 inhibits Increase urinary excretion of glucose Sulfonylureas Increase insulin secretion Thiazolidinediones Increase glucose uptake in muscle and fat Decrease HGP Canagliflozin Dapagliflozin Empagliflozin Glimepiride Glipizide Glyburide Pioglitazone Rosiglitazone Invokana Farxiga Jardiance Amaryl generic Glucotrol generic Dia eta, Glynase, Micronase, generic Actos Avandia FPG lowering PPG lowering GLP-1, glucagon-like peptide; HGP, hepatic glucose production; SGLT2, sodium glucose cotranspter 2. AGI = -glucosidase inhibits; BCR-QR = bromocriptine quick release; Coles = colesevelam; DPP4I = dipeptidyl peptidase 4 inhibits; FPG = fasting plasma glucose; GLP1RA = glucagon-like peptide 1 recept agonists; Met = metfmin; Mod = moderate; PPG = postprandial glucose; SGLT2I = sodium-glucose cotranspter 2 inhibits; SU = sulfonylureas; TZD = thiazolidinediones. *Mild: albiglutide and exenatide; moderate: dulaglutide, exenatide extended release, and liraglutide. 20 Continued on next slide Effects of Agents Available f DM2 Effects of Agents Available f T2D Met GLP1RA SGLT2I DPP4I TZD AGI Coles BCR-QR SU/ Glinide Insulin Pram NAFLD benefit SU/ Met GLP1RA SGLT2I DPP4I TZD AGI Coles BCR-QR Insulin Pram Glinide Mild Mild Neutral Neutral Mod Neutral Neutral Neutral Neutral Neutral Neutral Contraindicated contra- GU Exenatide Renal impairment/ GU in stage indicated infection 3B, 4, 5 CrCl <30 risk CKD mg/ml Dose Increased adjustment wsen hypo- hypo- May Increased risks of Neutral Neutral Neutral Neutral (except fluid glycemia glycemia linagliptin) retention risk and fluid retention SU/ Met GLP1RA SGLT2I DPP4I TZD AGI Coles BCR-QR Insulin Pram Glinide Mod to SU: mod marked Mild to Mod Mod Mild Mod Neutral Mild Neutral Glinide: (basal Mild mod* mild insulin premixed) Mod to marked (sht/ Mod to Mod to Mild Mild Mod Mild Mod Mild Mild Mod rapidacting marked marked insulin premixed) SU: mod to severe Hypoglycemia Mod to Neutral Neutral Neutral Neutral Neutral Neutral Neutral Neutral Glinide: Neutral severe* mild to mod Weight Slight loss Loss Loss Neutral Gain Neutral Neutral Neutral Gain Gain Loss GI adverse Mod Mod* Neutral Neutral* Neutral Mod Mild Mod Neutral Neutral Mod effects CHF Neutral Neutral Neutral Neutral Mod Neutral Neutral Neutral Neutral Neutral Neutral CVD Possible Neutral Neutral Neutral Neutral Neutral Neutral Safe? Neutral Neutral benefit Mod bone Bone Neutral Neutral Bone loss Neutral Neutral Neutral Neutral Neutral Neutral Neutral loss AGI = -glucosidase inhibits; BCR-QR = bromocriptine quick release; Coles = colesevelam; DPP4I = dipeptidyl peptidase 4 inhibits; GLP1RA = glucagon-like peptide 1 recept agonists; Met = metfmin; Mod = moderate; NAFLD, nonalcoholic fatty liver disease; SGLT2I = sodium-glucose cotranspter 2 inhibits; SU = sulfonylureas; TZD = thiazolidinediones. *Especially with sht/ rapid-acting premixed. AGI = -glucosidase inhibits; BCR-QR = bromocriptine quick release; Coles = colesevelam; CHF = congestive heart failure; CVD = cardiovascular disease; DPP4I = dipeptidyl peptidase 4 inhibits; GI = gastrointestinal; GLP1RA = glucagon-like peptide 1 recept agonists; GU = genitourinary; Met = metfmin; Mod = moderate; SGLT2I = sodium-glucose cotranspter 2 inhibits; SU = sulfonylureas; TZD = thiazolidinediones. *Caution in labeling about pancreatitis. Caution: possibly increased CHF hospitalization risk seen in CV safety trial. Fixed-Dose Combination Antihyperglycemic Agents Class Added Agent Available as DPP-4 inhibit SGLT2 inhibit Linagliptin empagliflozin Glyxambi Metfmin DPP-4 inhibit Alogliptin Linagliptin Saxagliptin Sitagliptin Kazano Jentadueto Kombilyze XR Metfmin glinide Repaglinide Prandimet Metfmin SGLT2 inhibit Metfmin sulfonylurea Metfmin thiazolidinedione Canagliflozin Dapagliflozin Glipizide Glyburide Pioglitazone Rosiglitazone* Janumet, Janumet XR Invokamet Xigduo XR Thiazolidinedione DPP-4 inhibit Pioglitazone alogliptin Oseni Thiazolidinedione sulfonylurea Pioglitazone Rosiglitazone Metaglip and generic Glucovance and generic ACTOplus Met Avandamet Duetact Avandaryl
5 Mrs. D, 90-year old Type 2 DM Case Study #1 Harms, 2012 Mrs. D has been diagnosed with diabetes f 10 years and comes to the clinic f a recheck. Combidities: HTN, hyperlipidemia Current meds: simvastatin 20 mg. daily, metoprolol 25 mg. BID, benazepril 10 mg. daily Last A1c 6.6%, FBG 120. Home glucose measurements repted as Lives in her own apartment, walks around her home, goes to church and once a week dinner with daughter. What should the NP do? All photos in this presentation are the sole property of Dixie Harms, ARNP SC, 49 year old female Case Study #2 October 2013 Glucose 298 A1C 12.9% fructoasamine 439 (nmal ) fasting insulin level 9 (nmal 2-27) C-peptide 2.2 (nmal 1.5 5) WEIGHT 191 LBS. BMI 30 Current meds NONE SC, 49-year old female January 2014 FBG 114 mg/dl A1c%--6.1% Total cholesterol 153 Trigs 63 HDL 44 LDL 96 Current Medication Metfmin 500 mg. 2 tablets BID WEIGHT 183 lbs SC, 49-year old female August 2014 FBG 130 A1c 6.0% Total cholesterol 183 Triglycerides 168 HDL 45 LDL 104 Current Medications Metfmin 500 mg. 2 tablets daily, lisinopril 5 mg. daily WEIGHT 175 lbs/bmi
6 SC, 49-year old female February 2015 Current medications Metfmin 500 mg. 2 tablets po BID, Lisinopril 5 mg. po QDAY, levothyroxine WEIGHT 184 lbs BMI 28.8 A1c 6.0% FBG 112 mg/dl Case Study #3 BH 62 year old female BH 62-year old female February 2012 WEIGHT 277 lb, BMI 46 A1C 6.0 FBG 101 mg/dl LIPIDS TC 186, trigs 105, HDL 50, LDL--115 MEDS Citalopram, ASA, sitagliptin/metfmin (Janumet) 50/500 one tablet po BID, Lisinopril/HCTZ 5/25 qday, fenofibrate 134 mg daily, levothyroxine Diabetes Meds Metfmin 1000 mg. BID, sitagliptin (Januvia) 100 mg. daily, pioglitazone (Actos) 45 mg. daily, levothyroxine A1c range , FBG 130s 180s Weight Maximum 285 lbs. Did not exercise Co-mbities HTN, hyperlipidemia, hypothyroidism, hypertriglyceridemia, depression BH 62 year old female May 2012 Laparoscopic gastric sleeve June 2012 Patient in f labs only WEIGHT A1C 5.3 FBG 88 mg/dl LIPIDS TC 191, TRIGS 102, HDL 54, LDL 115 MEDS none August 2012 Recheck WEIGHT 228 lbs, BMI 38 Meds Levothyroxine No labs done BH 62 year old female June 2013 WEIGHT 209 lbs, BMI 34.8 A1C 5.3% FBG 88 mg/dl LIPIDS TC 191, trigs 102, HDL 54, LDL 117 MEDS Levothyroxine 6
7 BH 62 year old female October 2013 WEIGHT 215 lbs, BMI 35 A1C 5.4% FBG 90 mg/dl LIPIDS TC 185, trigs 98, HDL 55, LDL 107 MEDS Levothyroxine Sodium-Glucose Transpter 2 (SGLT2) Examples Canagliflozin (Invokana) mg daily Dapagliflozin (Farxiga) 5-10 mg daily Empagliflozin (Jardiance) mg q am Target Organ: Kidney Actions: Inhibits SGLT2, reducing glucose reabsption and increasing urinary glucose excretion Side Effects: hyperkalemia, genital mycotic infection, increased cholesterol, increased magnesium, hypoglycemia, UTI, increased urination, increased hemoglobin, vulvovaginal pruritus, thirst, hypotension, constipation, fatigue, nausea, increased creatinine Contraindications: Type 1 DM, DKA, dehydration, hypotension, elderly hyperkalemia, increased creatinineclearance A1c Reduction Non-insulin Injectable Medications f DM2 Class Primary Mechanism of Action Agent(s) Available as GLP-1 recept agonists Increase glucose-dependent insulin secretion Albiglutide Dulaglutide Decrease glucagon secretion Exenatide Slow gastric emptying Exenatide XR Increase satiety Liraglutide Tanzeum Trulicity Byetta Bydureon Victoza GLP-1, glucagon-like peptide; HGP, hepatic glucose production; SGLT2, sodium glucose cotranspter 2. Incretin Mimetics Examples Exanitide (Byetta) 5 10 mcg BID subq Liraglutide (Victoza) mg q day subq Exanitide (Bydureon) 2 mg subq q week Albiglutide (Tanzeum) 30 mg subq weekly Dulaglitide (Trulicity) mg subq weekly Target Organ: pancreas Side Effects: hypoglycemia, severe (with sulfonylurea), pancreatitis, renal failure, nausea, hypoglycemia (with sulfonylurea), vomiting, jitteriness, dizziness, headache, dyspepsia, decreased appetite, GERD Contraindications: Type 1 DM, DKA, gastroparesis, GI disease, pancreatitis, severe renal impairment Black box warning: Thyroid C-cell tum risk Case Study #4 7
8 RG, 56-year old male RG, 56-year old male Diagnosed with diabetes in 2010 Salesman spends great deal of time on the road, eats in restaurants, no regular exercise Has been on metfmin 500 mg BID since 2010 Diabetic education September 2011 October 2011 A1c-7.1% January 2012 A1c 6.2% August 2012 A1c 6.0% April 2013 A1c 6.60% December 2013 A1c 7.5% FBG--141 WEIGHT/BMI 284/37 MEDS metfmin 500 mg. BID RG, 56-year old male April 2014 A1c 8.3% FBG 187 WEIGHT/BMI 285/37 Lipids TC 196, trigs 193, HDL 42, LDL--117 Meds Metfmin 500 mg. 2 tabs BID, benazepril 10 mg. daily Case Study #5 KT, 32 YEARS OLD Female with DM2 Comes in f diabetic education/med adjustment Histy diabetes x 2 years, no insurance until now Limiting carbs to grams per meal No exercise Labs: TC 175, HDL 28, LDL, 98, trigylcerides 198, Chol/HDL ratio 5.5 FBG 193, A1c 8.9% Meds: Glipizide 5 mg. daily, Sitagliptin (Januvia) 10 mg. daily Glargine (Lantus) 80 units subq daily Lisinopril 5 mg. daily WEIGHT 358 POUNDS. What should the NP do? Case Study #6 8
9 Mr. T is a 48-year old male who has had diabetes f 5 years. He is very active in school activities football team official, school bus driver. Combidities: Obesity (BMI 45), hyperlipidemia, hypertryglyceridemia Current medications: glimepiride 8 mg. daily, metfmin 1000 mg. BID, simvastatin 40 mg. daily, pioglitazone 30 mg. daily, lisinopril 20 mg. daily Last medical exam me than 6 months ago Weight 345 pounds Recent labs: FBG 258, A1C 11.4%, TC 350, Trigs 550, HDL 32, LDL?., microalbuminuria Patient resistant to take medication. He states that he can t change his diet because he is always hungry and never feels full. What should the NP do? Continue ACE/ARB Increase statin/add fenofibrate niacin Diabetes medications? Insulin Incretin mimetic Therapeutic lifestyle changes Discussed diet SMBG BID Exercise Recheck 3 weeks Three weeks later Patient repts Diet splitting meals with wife when eating out. Adds that he can t eat as much as usual because he feels full Exercise walking every evening Meds taking medications regularly, denies problems with injection of liraglutide Glucoses Checking BID, repts FBG have dropped from 250s to 150s on 1.2 mg daily Feeling good with me energy, vision clearing 9 pound weight loss 3 months later FBG 125, A1C 7.5%, TC 201, Trigs 158, HDL 35, LDL 114, negative microalbuminuria BP 124/76, weight down 14 pounds Taking liraglultide 1.8 mg daily Appetite fairly well controlled, has occasional breakthroughs but still watching diet fair Other meds: simvastatin 40 mg. daily, pioglitazone 30 mg. daily, lisinopril 20 mg. daily, metfmin 1000 mg. BID What should the NP do? January 2014 (pt hasn t had recheck >9 months) Wife going thru chemo f breast cancer Weight 356 pounds Not exercising watching diet A1c 9.8%, FBG 180 mg/dl Meds: liraglutide 1.8 mg daily, simvastatin 40 mg. daily, pioglitazone 45 mg. daily, metfmin 1000 mg. BID, lisinopril 20 mg. daily November 2014 Weight 336 pounds Now exercising & watching diet A1c 7.8%, FBG 170 mg/dl Meds: liraglutide 1.8 mg daily, simvastatin 40 mg. daily, pioglitazone 45 mg. daily, metfmin 1000 mg. BID, lisinopril 20 mg. daily, canagliflozin (Invokana) 100 mg. daily 9
10 Common Principles in AACE/ACE and ADA/EASD T2D Treatment Algithms ADA/EASD T2D Treatment Algithm: Sequential Insulin Strategies # Injections 1 Basal Insulin (usually with metfmin /- other non-insulin agent) Complexity low Start: 10U/day U/kg/day Adjust: 10-15% 2-4 U once-twice weekly to reach FBG target. F hypo: Determine & address cause; ê dose by 4 units 10-20%. Individualize glycemic goals based on patient characteristics Promptly intensify antihyperglycemic therapy to maintain blood glucose at individual targets Combination therapy necessary f most patients Base choice of agent(s) on individual patient medical histy, behavis and risk facts, ethno-cultural background, and environment Insulin eventually necessary f many patients SMBG vital f day-to-day management of blood sugar All patients using insulin Many patients not using insulin 2 3 If not controlled after FBG target is reached ( if dose > 0.5 U/kg/day), treat PPG excursions with meal-time insulin. (Consider initial Add 1 rapid insulin* injections GLP-1-RA Change to befe largest meal trial.) premixed insulin* twice daily Start: 4U, 0.1 U/kg, 10% basal dose. If Start: Divide current basal dose into 2/3 AM, A1c<8%, consider ê basal by same amount. 1/3 PM 1/2 AM, 1/2 PM. Adjust: é dose by 1-2 U 10-15% oncetwice weekly until SMBG target reached. twice weekly until SMBG target reached. Adjust: é dose by 1-2 U 10-15% once- F hypo: Determine and address cause; F hypo: Determine and address cause; ê cresponding dose by 2-4 U 10-20%. ê cresponding dose by 2-4 U 10-20%. If not If not controlled, Add 2 rapid insulin* injections controlled, consider basalbolusbolus. befe meals ('basal-bolus consider basal- ) Start: 4U, 0.1 U/kg, 10% basal dose/meal. If A1c<8%, consider ê basal by same amount. Adjust: é dose by 1-2 U 10-15% once-twice weekly to achieve SMBG target. F hypo: Determine and address cause; ê cresponding dose by 2-4 U 10-20%. mod. 55 Flexibility me flexible less flexible 56 Insulin Therapy Generic name Brand name Onset of Action Duration Basal insulins (long-acting) Glargine detemir U300 glargine NPH Degludec U-100 & U-200 Lantus Levemir Toujeo NPH Tresiba 1 hour 1 hour 6 hours minutes 24 hours 24 hours 36 hours hours 42 hours Rapid-acting insulins Lispro Humalog aspart Novolog 15 minutes 3 to 5 hours glulisine Apidra Sht-acting Regular Regular 30 to 60 minutes 5 to 8 hours Pre-mixed insulin 75/25, 70/30 50/50 Humalog Mix 75/25, Novolog 75/25 10 to 15 minutes 75/25 10 to 16 hours 70% NPH/30% regular 70/30, Humalog Mix 50/50, 70/30 5 to 15 minutes 70/30 10 to 16 hours Novolin 70/30 Humulin 70/30 50/50 10 to 15 minutes 50/50 10 to 16 hours 70% NPH/30% regular 30 to 70% NPH/30% regular 10 to 60 minutes 16 hours Rapid-acting inhaled insulin Afrezza Afrezza 10 to 20 minutes 3 hours 57 Mr. G, 78-year male with Type 2 DM Case Study #7 Mr. G has had diabetes f over 10 years Current meds: metfmin 500 mg. BID, pioglizatone 30 mg. daily, glimepiride 8 mg daily, benazepril 10 mg. daily, simvastatin 40 mg. daily Last A1c 9.6%, FBG 216. Related signs/symptoms: increasing swelling in lower extremities, weight gain, elevated creatinine Exercise: None except yardwk Diet: No special diet What should the NP do? 10
11 Mr. G, 78-year male with Type 2 DM Ms. N, 62-year old DM2 Discontinue metfmin Discontinue pioglitazone Continue glimepiride, benazepril and simvastatin Encourage TLC Start glargine 10 units subq daily SMBG BID Follow-up labs in 3 months Comes in f routine diabetes check after last check 8 months ago A1c 10.2%, FBG 216 this am SMBG not routinely Not watching diet, no exercise, not always compliant with medications. Currently on glargine 80 units BID Taking units lispro with meals (??) Also on ACE, fenofibrate, statin Intolerant of metfmin (all types) Thank you. Any Questions? Thank you. 11
Objectives. How Medicine Works to Control Blood Sugar Levels. What Happens When We Eat? What is diabetes? High Blood Glucose (Hyperglycemia)
How Medicine Works to Control Blood Sugar Levels Stacie Petersen, RN, CDE Objectives Define Diabetes List how medications work (ominous octet) Identify side effects of medications for diabetes What is
More informationDiabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018
Diabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018 Learning Objectives Identify medication classes available for treatment of individuals with diabetes. Demonstrate understanding
More informationRPCC Pharmacy Forum. The Type 2 Diabetes Issue. Type 2 Diabetes: The Basics
Nov/Dec 2015 Issue 11 RPCC Pharmacy Forum Special Interest Articles: Diabetes Medication Chart Insulin Chart Afreeza Did you know? Exanatide, marketed as Byetta, is the synthetic form of exendin-4, which
More informationDiabetes Update 2018: Challenging Transitions. Patricia A. Daly, MD, FACP, FACE Medical Director for Diabetes Valley Health System
Diabetes Update 2018: Challenging Transitions Patricia A. Daly, MD, FACP, FACE Medical Director for Diabetes Valley Health System 1 Patricia A. Daly, MD, FACP, FACE Medical Director for Diabetes Valley
More informationClinical Cases in Diabetes Management. Joseph Cook D.O.
Clinical Cases in Diabetes Management Joseph Cook D.O. Objectives State the prevalence of Diabetes Mellitus in Ohio State the percentage of diabetic patients in the U.S. treated by Primary Care Physicians
More informationOral Medication for the Management of Diabetes Mechanism of. Duration of Daily Dosing Action
Glyburide (Micronase, Diabeta, Glynase) Glipizide (Glucotrol) Glipizide XL (Glucotrol XL) Glimepiride (Amaryl) Prandin (Repaglinide) Starlix (Nateglinide) 1.25, 2.5, 5mg tabs, Dosing: 2.5-20 mg 12- (Glynase:
More informationDiabetes Update 2018: Challenging Transitions. Patricia A. Daly, MD, FACP, FACE Medical Director for Diabetes Valley Health System
Diabetes Update 2018: Challenging Transitions Patricia A. Daly, MD, FACP, FACE Medical Director for Diabetes Valley Health System 1 Patricia A. Daly, MD, FACP, FACE Medical Director for Diabetes Valley
More informationDiabetes Treatment Guidelines
Diabetes Treatment Guidelines For more comprehensive information about current approaches to the diagnosis and treatment of diabetes, visit the American Diabetes Association Standards of Medical Care 2018
More informationPharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17
Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)
More informationObjectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors
No disclosure Objectives Recognize all available medical treatment options for diabetes Individualize treatment and glycemic target based on patient factors Should be able to switch to more affordable
More informationWhat s New in Diabetes Medications. Jena Torpin, PharmD
What s New in Diabetes Medications Jena Torpin, PharmD 1 Objectives Discuss new medications in the management of diabetes Understand the mechanism of the medications discussed Understand the side effects
More information1/15/2018. Disclosures. Current Diabetes Medications. Objectives NON-INSULIN AGENTS. Diabetes Med Classes. Mealtime
Disclosures Current Diabetes Medications None Claire Baker, M.D. Diabetes & Endocrine Associates January 24, 2018 Objectives Identify categories of diabetes medications Understand the pharmacology of diabetes
More informationNon-Insulin Diabetes Medications Summary
Non-Insulin Diabetes Medications Summary Medications marked with an asterisk (*) can cause hypoglycemia INSULIN SECRETAGOGUES Sulfonylureas* GLYBURIDE* (Diabeta) (Micronase) production. Side effects: Potential
More informationWhat s New in Diabetes Treatment. Disclosures
What s New in Diabetes Treatment Shiri Levy M.D. Henry Ford Hospital Senior Staff Physician Service Chief, West Bloomfield Hospital Endocrinology, Metabolism, Bone and Mineral Disorders Disclosures None
More informationWhat the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin
Diabetes s Oral s - Pills These are some of the pills that are currently available in Canada to treat diabetes. Each medication has benefits and side effects you should be aware of. Your diabetes team
More informationDiabetes Update Bryan Heart Conference September 5, 2015 Shannon Wakeley, MD. Disclosures. Objectives 9/1/2015
Diabetes Update Bryan Heart Conference September 5, 2015 Shannon Wakeley, MD Disclosures I speak on behalf of the following companies: Astra Zeneca, Boehringer Ingelheim, Johnson & Johnson, Sanofi and
More informationAntihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014
Antihyperglycemic Agents in Diabetes Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014 Objectives Review 2014 ADA Standards of Medical Care in DM as they
More informationSilvio E. Inzucchi MD Section of Endocrinology Yale School of Medicine
Gegia Chapter of the American Association of Clinical Endocrinologists, 2017 Annual Meeting January 28, 2017 Silvio E. Inzucchi MD Section of Endocrinology Yale School of Medicine DIABETES MANAGEMENT GUIDELINES
More informationAdvanced Practice Education Associates. Endocrine
Advanced Practice Education Associates Endocrine Overview Diabetes Thyroid Disease 162 Copyright 2016 Advanced Practice Education Associates DIABETES MELLITUS What is the BMI cut point for screening adults
More informationDIABETES. overview of pharmacologic agents used in the management of. Overview 4/3/2014 OBJECTIVES. Injectable Agents
overview of pharmacologic agents used in the management of DIABETES Kyle Roberts, Pharm.D. PGY-1 Pharmacy Resident Saint Alphonsus RMC 1. List the different classes of diabetes medications, including the
More informationDiabetes Mellitus II CPG
1 Diabetes Mellitus II CPG Candidates for Screening Integrated Complex Care Patients: Check Yearly Prediabetes: Check Yearly No Diabetes Mellitus (DM) Risk Factors: Check at Age 45, Repeat Every 3 Years
More informationTable 1. Antihyperglycemic agents for use in type 2 diabetes
Table 1. Antihyperglycemic agents for use in type 2 diabetes DRUG IN ALPHA-GLUCOSIDASE INHIBITOR: inhibits pancreatic alpha-amyle and intestinal alpha-glucoside Acarbose (Glucobay) 0.6% Negligible Not
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationDiabetes Medications: Oral Anti-Hyperglycemic Medications
Diabetes Medications: Oral Anti-Hyperglycemic Medications Medication Types 1. Biguanides 2. Sulfonylureas 3. Thiazolidinediones (TZDs) 4. Alpha-Glucosidase Inhibitors 5. D-Phenylalanine Meglitinides 6.
More informationPharmacologic Agents for Treatment of Type 2 Diabetes
Pharmacologic Agents for Treatment of Type 2 Diabetes SCAN Drugs Medication Biguanides 1 1 er uncoated tabs 500 mg & 750 mg Sulfonylureas 1 1 500 850 mg QD - TID 500 2000 mg glimepiride 1 1 1 8 mg glipizide
More informationDM Fundamentals Class 4 Meds for Type 2
DM Fundamentals Class 4 Meds for Type 2 Beverly Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Copyright 1999 2015, Diabetes Education Services, All Rights Reserved. Diabetes Meds
More informationManagement of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association (ADA) and the European Association f the Study of Diabetes
More informationOral and Injectable Non-insulin Antihyperglycemic Agents
Appendix 5: Diabetes Education and Medical Management in Adults with Diabetes Oral and Injectable Non-insulin s This directive will be implemented by RPhs, RNs or RDs who have been deemed authorized implementers.
More informationDM Fundamentals Class 4 Meds for Type 2
DM Fundamentals Class 4 Meds for Type 2 Beverly Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Copyright 1999 2015, Diabetes Education Services, All Rights Reserved. Diabetes Meds
More informationInitiating Injectable Therapy in Type 2 Diabetes
Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current
More informationImproving Patient Outcomes with Individualized Therapy in the Management of Type 2 Diabetes
Improving Patient Outcomes with Individualized Therapy in the Management of Type 2 Diabetes Timothy S. Reid, M.D. Mercy Diabetes Center Janesville, WI Duality Statement Dr. Reid is a Speaker and Consultant
More informationJonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA 2012 Virginia Mason Medical
Jonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA There is no conflict of interest that could be perceived as prejudicing the impartiality
More informationPhysician Drug Reference Chart for Diabetes Antidiabetic Medications
Drug Class Compound Brand Name Mechanism of Action Advantages Disadvantages Alpha-glucosidase inhibitors Medium Cost by Bayer Healthcare, Pfizer, Takeda Research Acarbose Miglitol Voglibose Precose Glyset
More informationSociety for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery
Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Girish P. Joshi, MB BS, MD, FFARCSI Anesthesia & Analgesia
More informationImages have been removed from the PowerPoint slides in this handout due to copyright restrictions. Insulins. Rapid Short Intermediate Long Mix
Diabetes Medications Diabetes Medications Type 1 Insulin is needed Type 2 Oral Diabetes Medications Or Oral Diabetes Medications plus Insulin Or Insulin Alone Diabetes Medications Secretagogues Glipizide
More information4/9/2018 HOW TO REGULATE DIABETES MEDICATIONS. By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE. Diagnosis
HOW TO REGULATE DIABETES MEDICATIONS By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE Diagnosis 1 NORMAL BODY The normal pancreas releases one unit of insulin every hour all day. The normal pancreas
More informationDiabetes Update 10/12/2017. Section #1 OBJECTIVE. Lab features to consider:
Section #1 OBJECTIVE Diabetes Update Fall 2017 Lyle Myers BE ABLE TO DIFFERENTIATE TYPE 1 FROM TYPE 2 DIABETES Clinical features: - age at onset - body weight/bmi - family history - treatment history -
More informationGlycemic Management of Type 2 Diabetes. Gail Nunlee-Bland, M.D. Professor Medicine & Pediatrics Director, Diabetes Treatment Center Howard University
Glycemic Management of Type 2 Diabetes Gail Nunlee-Bland, M.D. Professor Medicine & Pediatrics Director, Diabetes Treatment Center Howard University 1 None Disclosures Learning Objectives Understand the
More informationClinical Pharmacotherapeutic Applications of the American Diabetes Association Standards of Care 2018
Clinical Pharmacotherapeutic Applications of the American Diabetes Association Standards of Care 2018 RACHEL NAIDA, PHARMD, CDE CLINICAL ASSOCIATE PROFESSOR UNIVERSITY OF NEW ENGLAND COLLEGE OF PHARMACY
More informationNew Therapies for Diabetes
Type 2 diabetes is increasingly prevalent New Therapies for Diabetes Lynn Mack, M.D. Associate Professor Diabetes, Endocrinology, & Metabolism The Nebraska Medical Center lmack@unmc.edu No Conflicts of
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationInsulin and Post Prandial
Insulin and Post Prandial Pr Luc Martinez PCDE Meeting Barcelona 2016 Conflicts of interest disclosure Advis consultant f Amgen Inc.; AstraZeneca Pharmaceuticals LP; GlaxoSmithKline; Ipsen; Lilly; Mayoly
More informationDIABETES (1 of 5) Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10. Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10 $0 $0 $0
Metformin DIABETES (1 of 5) Glucophage Glucophage XR ER $7 (500mg) $7 (500mg) $5 $5 500mg, 750mg only 500mg, 750mg only Sulfonylurea/Combinations Amaryl Glucotrol glimepiride glipizide $5 $5 Glucotrol
More information6/1/2018. Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE
Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE 1 2 3 Sulfonylureas Glipizide Glyburide Glimeperide 4 Metformin Gold
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Gretchen Ray, PharmD, PhC, BCACP, CDE Associate Professor, UNM College of Pharmacy January 28, 2018 gray@salud.unm.edu OBJECTIVES Describe the most
More informationClinical Practice Guidelines
Clinical Practice Guidelines Diabetes Objective The purpose is to guide the appropriate diagnosis and management of Diabetes. This guideline is designed to assist the clinician by providing a framework
More informationUpdate on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015
Update on Therapies for Type 2 Diabetes: 2015 Angela D. Mazza, DO July 31, 2015 Objectives To present the newer available therapies for the management of T2D To discuss the advantages and disadvantages
More informationDIABETES. Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes. November 2013
DIABETES Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes November 2013 mbruskewitz@outlook.com Objectives Part 1 Overview of Endocrine Physiology Pathophysiology of Diabetes Diabetes
More informationFARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)
Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your
More informationThe Death of Sulfonylureas? A Review of New Diabetes Medications
The Death of Sulfonylureas? A Review of New Diabetes Medications Kelly Hoenig, Pharm.D., BCPS Cedar Rapids Family Medicine Residency 2/4/17 Objectives Review GLP-1 Agonists, DPP-IV Inhibitors and SGLT-2
More informationMultiple Factors Should Be Considered When Setting a Glycemic Goal
Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent
More informationManagement of Type 2 Diabetes Mellitus. Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism
Management of Type 2 Diabetes Mellitus Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism Disclosures Working for Intermountain Healthcare Some of the views represented are the opinion of ABIM-certified
More informationRebecca Newberry APRN MS CDE
Current Diabetes Medications Nursing Implications and Applications Rebecca Newberry APRN MS CDE Methodist Center for Diabetes and Nutritional Health Disclosures Objectives Speakers Bureaus/Consulting Board
More informationWayne Gravois, MD August 6, 2017
Wayne Gravois, MD August 6, 2017 Americans with Diabetes (Millions) 40 30 Source: National Diabetes Statistics Report, 2011, 2017 Millions 20 10 0 1980 2009 2015 2007 - $174 Billion 2015 - $245 Billion
More information7/8/2016. Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine
Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine Participation in investigator initiated clinical research supported by: Merck Boehringer Ingelheim Novo Nordisk Astra Zeneca
More information2018 Diabetes Summit Managing Diabetes: An Art and a Science
2018 Diabetes Summit Managing Diabetes: An Art and a Science Natasha Petry, PharmD, BCACP NDSU College of Health Professions, School of Pharmacy, Department of Pharmacy Practice Patient-Centered Medical
More information9/29/ Disclosure. Learning Objectives. Diabetes Update: Guidelines, Treatment Options & Trends
+ Diabetes Update: Guidelines, Treatment Options & Trends Melissa Max, PharmD, BC-ADM, CDE Assistant Professor of Pharmacy Practice Harding University College of Pharmacy + Disclosure Conflicts Of Interest
More informationDiabetes Basics. Type 1 diabetes The body cannot make insulin Requires insulin injection Is not treated with oral diabetes medicines (pills)
Diabetes Basics What is Diabetes? Diabetes is a disease in which the pancreas is unable to make insulin or the body is unable to use insulin or both. This leads to high blood sugar levels in the blood.
More informationVery Practical Tips for Managing Type 2 Diabetes
Very Practical Tips for Managing Type 2 Diabetes Jean-François Yale, MD, FRCPC McGill University Health Centre, Montreal, Canada Jean-francois.yale@mcgill.ca www.dryale.ca OBJECTIVES DISCLOSURES The participant
More informationPharmacology. Kacy Aderhold, MSN, APRN-CNS, CMSRN
Pharmacology Kacy Aderhold, MSN, APRN-CNS, CMSRN Biguanides Decreases hepatic glucose production and improves insulin sensitivity (increases number of insulin receptors) Common Adverse Reaction: diarrhea
More informationTABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations
177 TABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations Formulary
More informationDiabetes Oral Agents Pharmacology. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
Diabetes Oral Agents Pharmacology University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 Learning Objectives Understand the role of the utilization of free
More informationTABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations
177 TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations Formulary Coverage Indication for use with: INSULIN THERAPY NS NB NL PE ADULTS PEDIATRICS PREGNANCY BOLUS
More informationManaging Complex Diabetes Cases: Medication Update. Celia Levesque MSN, RN, CNS-BC, CDE, BC-ADM
Managing Complex Diabetes Cases: Medication Update Celia Levesque MSN, RN, CNS-BC, CDE, BC-ADM clevesqu@mdanderson.org Objectives Describe how each diabetes medication class is used to treat diabetes Differentiate
More informationSGLT2 Inhibition in the Management of T2DM: Potential Impact on CVD Risk
Managing Diabetes & CVD: Expling New Evidence & Opptunities ESC Congress, London, UK 30 August, 2015 SGLT2 Inhibition in the Management of T2DM: Potential Impact on CVD Risk Silvio E. Inzucchi MD Yale
More informationAge-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes
Age-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes Obesity (BMI 30 kg/m 2 ) 1994 2000 2009 No Data 26.0% Diabetes 1994 2000 2009
More informationORAL AGENTS OLD & NEW FOR THE MANAGEMENT OF T2DM
ORAL AGENTS OLD & NEW FOR THE MANAGEMENT OF T2DM ECHO-Diabetes July 21, 2016 VERONICA BRADY, PHD, FNP-BC, BC-ADM, CDE OBJECTIVES Overview of Diabetes Oral hypoglycemic agents Define various classes of
More informationDiabetes Management: A diagnostic perspective
Diabetes Management: A diagnostic perspective Images: http://www.engadget.com/2009/09/23/bayer-introduces-countour-usb-glucose-meter/ http://www.medtronicdiabetes.com/treatment-and-products/minimed-530g-diabetes-system-with-enlite
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationPharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes
Pharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes Brooke Hudspeth, PharmD, CDE, MLDE Director of Diabetes Prevention, Kroger Pharmacy Adjunct Assistant Professor, University
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationNewer Drugs in the Management of Type 2 Diabetes Mellitus
Newer Drugs in the Management of Type 2 Diabetes Mellitus Dr. C. Dinesh M. Naidu Professor of Pharmacology, Kamineni Institute of Medical Sciences, Narketpally. 1 Presentation Outline Introduction Pathogenesis
More informationWhat s New on the Horizon: Diabetes Medication Update
What s New on the Horizon: Diabetes Medication Update Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors, and what s coming Revised ADA/EASD and AACE guidelines:
More informationOral and Injectable Medication Options for Diabetes Treatment
Oral and Injectable Medication Options for Diabetes Treatment Presented by: Dr. Daphne E. Smith, Pharm.D., CDE Clinical Assistant Professor/Clinical Pharmacist-University of Illinois at Chicago College
More informationType 2 Diabetes Mellitus 2011
2011 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Diabetes Mellitus Diagnosis 2011 Diabetes Mellitus Fasting Glucose
More informationI. General Considerations
1 2 3 I. General Considerations A. Type I ( Juvenile Onset or IDDM) IDDM results from autoimmune destruction of beta cells inability to secrete insulin --> ketone formation --> DKA 4 Diabetic Ketoacidosis
More informationAgenda. Indications Different insulin preparations Insulin initiation Insulin intensification
Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations
More informationHow can we improve outcomes in Type 2 diabetes?
How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management Identify and treat all risk factors Use rational pharmacological therapy
More informationWhat s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA
What s New on the Horizon: Diabetes Medication Update Michael Shannon, MD Providence Endocrinology, Olympia WA 1 Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors,
More informationMultiple Small Feedings of the Mind: Diabetes. Sonja K Fredrickson, MD, BC-ADM March 7, 2014
Multiple Small Feedings of the Mind: Diabetes Sonja K Fredrickson, MD, BC-ADM March 7, 2014 Question 1: Setting A1c Goals Describe the evidence based approach to determining the target HgbA1c in different
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Jessica Conklin, PharmD, PhC, BCACP, CDE, AAHIP Associate Professor, UNM College of Phar macy jeconklin@salud.unm.edu Luis Gonzales, PharmD, PhC UNM
More informationDrug Class Review Newer Diabetes Medications and Combinations
Drug Class Review Newer Diabetes Medications and Combinations Final Update 2 Report July 2016 The purpose reports is to make available information regarding the comparative clinical effectiveness and harms
More information第十五章. Diabetes Mellitus
Diabetes-1/9 第十五章 Diabetes Mellitus 陳曉蓮醫師 2/9 - Diabetes 羅東博愛醫院 Management of Diabetes mellitus A. DEFINITION OF DIABETES MELLITUS Diabetes Mellitus is characterized by chronic hyperglycemia with disturbances
More informationSide Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors. Bryce Fukunaga PharmD April 25, 2018
Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors Bryce Fukunaga PharmD April 25, 2018 Objectives For each drug class: Identify the overall place in therapy Explain the mechanism of action
More information2/17/2016. Objectives. Define. Hey Sugar! DMII Management in Hospice Care
Hey Sugar! DMII Management in Hospice Care Michelle Huber, R.Ph., PharmD.,CGP Objectives Review treatment for hyperglycemia discussing how these medications work, hypoglycemia risk, special considerations.
More informationDiabetes 2016: Strategies for achieving optimal diabetes control
PHASE Safety Net Community Benefit Diabetes 2016: Strategies for achieving optimal diabetes control Presented by: Lisa Gilliam, MD, PhD Clinical Leader Diabetes Program Kaiser Permanente Northern California
More informationDipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol
Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationNEW DIABETES CARE MEDICATIONS
NEW DIABETES CARE MEDICATIONS James Bonucchi DO, ECNU, FACE Adult Medicine and Endocrinology Specialists Disclosures Speakers bureau Sanofi AZ BI Diabetes Diabetes cost ADA 2017 data Ever increasing disorder.
More informationUpdate on Diabetic Medications UMA SUNDARAM, M.D. DIABETES & ENDOCRINE ASSOCIATES APRIL 07, 2018
Update on Diabetic Medications UMA SUNDARAM, M.D. DIABETES & ENDOCRINE ASSOCIATES APRIL 07, 2018 Disclosure NONE Objectives To identify different categories of diabetes medications Understand the pharmacology
More informationPathogenesis of Type 2 Diabetes
9/23/215 Multiple, Complex Pathophysiological Abnmalities in T2DM incretin effect gut carbohydrate delivery & absption pancreatic insulin secretion pancreatic glucagon secretion HYPERGLYCEMIA? Pathogenesis
More informationGlucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol
Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationcontinuing education for pharmacists
continuing education for pharmacists 2016 AACE/ACE Guidelines on Type 2 Diabetes Management and New Glycemic Control Agents Amanda R. Kriesen, R.Ph., PharmD, and Erin Bastick, R.Ph., PharmD Volume XXXV,
More informationA Practical Approach to the Use of Diabetes Medications
A Practical Approach to the Use of Diabetes Medications Juan Pablo Frias, M.D., FACE President, National Research Institute, Los Angles, CA Clinical Faculty, University of California, San Diego, CA OUTLINE
More informationDeaths Hospitalizations Company. Takeda Pharmaceuticals. Takeda Pharmaceuticals. Takeda Pharmaceuticals. Janssen Pharmaceuticals
Takeaways: Diabetes Drug Investigation From: BSardi@aol.com Sent: Mon, Dec 22, 2014 at 10:51 am To: Cc: gemcap2@reagan.com martie.whittekin@verizon.net, katjames008@gmail.com clip_image002.jpg (64.5 KB)
More informationPreventing Heart Attacks and Strokes Every Day (PHASE) RCHC Medication Titration Algorithm
Preventing Heart Attacks and Strokes Every Day (PHASE) RCHC Medication Algorithm Updated 9/13/2017 PHASE Populations DM: type 2 ASCVD: hx heart attack/cad, CVA, TIA, AAA, Sx PAD Lifestyle Modifications
More informationType II Diabetes Improving Blood Sugar Control. Geneva Clark Briggs, Pharm.D., BCPS
Type II Diabetes Improving Blood Sugar Control Geneva Clark Briggs, Pharm.D., BCPS Overview Importance of glucose control State of control Review available therapies Helping patients achieve control The
More information9/12/2014. Main Pathophysiological Defect in T1DM. Main Pathophysiological Defects in T2DM. Personalizing Diabetes Care: The Alphabet Soup of Options
9/12/2014 Baptist Health South Florida 13th Annual Primary Focus Symposium June 28, 2014 Silvio Inzucchi MD Section of Endocrinology Yale University School of Medicine Half-Century of HTN & T2DM Medications
More informationThe Community Pharmacist s Role in Diabetes Treatment
CONTINUING EDUCATION The Community Pharmacist s Role in Diabetes Treatment By Kimberly Ference, PharmD U pon completion of this activity, the pharmacist should be able to achieve these directives: 1. Describe
More informationDept of Diabetes Main Desk
Dept of Diabetes Main Desk 01202 448060 Glucose management in Type 2 Diabetes in Adults The natural history of type 2 diabetes is for HbA1c to deteriorate with time. A stepwise approach to treatment is
More informationReviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate
Reviewing Diabetes Guidelines Newsletter compiled by Danny Jaek, Pharm.D. Candidate AL AS KA N AT IV E DI AB ET ES TE A M Volume 6, Issue 1 Spring 2011 Dia bet es Dis pat ch There are nearly 24 million
More information